Crescent Biopharma, Inc.
NASDAQ:CBIOBiotechnology
-$0.49 today
- Market cap
- $482.30M
- Beta
- 1.15
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$5.33
Volume 0.33M
Average 0.28M
CBIO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Crescent Biopharma, Inc.NASDAQ: CBIO
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $7.87M rose 118.7% year over year, ahead of the +100.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 7.6% from the prior quarter. Over 3 fiscal years it compounded at +10.0% a year.
Context
- Selling, general & admin amounted to 234.1% of revenue in FY2025.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $1.8B (+6974.6%) for the fiscal year ending Dec 2026, a step up from the +55.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $7.87M+7.6% QoQ
- Last fiscal yearDec 2025
- $25.39M+55.5% YoY
- LTMMar 2026
- $29.66M+100.0% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 25.39M USD
- Year-over-year change
- +55.5%
- 4-year CAGR
- +10.4%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.39M | +55.5% |
| FY2024 | 2024-12-31 | 16.32M | -15.0% |
| FY2023 | 2023-12-31 | 19.21M | +0.7% |
| FY2022 | 2022-12-31 | 19.09M | +11.5% |
| FY2021 | 2021-12-31 | 17.12M | — |
Selling, General & Admin vs competitors
How CBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +100.0% is the 3rd highest of 10, against a peer median of +9.0%.
- Selling, general & admin amounts to 249.6% of revenue for CBIO, versus a peer median of 89.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $15.14B USD | +24248.6% | -5.7% | 5694.1% | |
| LTM Jun 2026 | $106M USD | -7.8% | +1.9% | 90.6% | |
| LTM Sep 2026 | $51.3M USD | +21.7% | +17.2% | 45802.7% | |
| LTM Mar 2026 | $38.15M USD | -27.9% | -12.7% | 24.3% | |
| LTM Mar 2026 | $31.1M USD | -1.0% | -11.4% | 87.5% | |
| LTM Mar 2026 | $29.66M USD | +100.0% | +10.0% | 249.6% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥21.46M CNY | +128.2% | -71.8% | — |
| LTM Mar 2026 | $18.51M USD | +10.2% | +13.1% | — | |
| LTM Mar 2026 | $9.36M USD | -6.3% | -5.7% | 12.9% | |
| LTM Mar 2026 | $8.11M USD | +9.0% | +0.2% | — | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CBIO) | — | +9.0% | -5.7% | 89.1% | |
Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.16M | 75K | 10K | 0 | 10.84M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.16M | 75K | 10K | 0 | 10.84M |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | 100.0% |
| Research & Development | 47.49M | 28.39M | 20.07M | 28.06M | 138.09M |
| Selling, General & Admin | 17.12M | 19.09M | 19.21M | 16.32M | 25.39M |
| Operating Expenses | 64.61M | 47.48M | 39.29M | 49.9M | 163.48M |
| Depreciation & Amortization | 264.6K | 207.15K | 153.3K | 35.17K | 84K |
| EBITDA | (63.18M) | (47.2M) | (39.12M) | (44.17M) | (149.67M) |
| EBITDA Margin | -5447.9% | -62927.6% | -391213.5% | — | -1380.2% |
| Operating Income | (63.45M) | (47.4M) | (39.28M) | (49.9M) | (152.63M) |
| Operating Margin | -5470.7% | -63204.4% | -392752.9% | — | -1407.5% |
| Interest Income | 19.77K | 714.52K | 2.38M | 1M | 2.88M |
| Interest Expense | 0 | 0 | 0 | 852K | 2.19M |
| Other Income / Expenses | 19.77K | 714.96K | 2.38M | 1.37M | 690K |
| Income Before Tax | (63.43M) | (46.69M) | (36.9M) | (48.52M) | (151.94M) |
| Pre-Tax Margin | -5469.0% | -62251.1% | -368987.8% | — | -1401.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 2M |
| Net Income | (63.43M) | (46.69M) | (36.9M) | (48.52M) | (153.94M) |
| Net Margin | -5469.0% | -62251.7% | -368994.2% | — | -1419.6% |
| EPS (Basic) | (1.23) | (0.89) | (0.58) | (1.40) | (14.78) |
| EPS (Diluted) | (1.23) | (0.89) | (0.58) | (1.40) | (14.78) |
| Weighted Avg Shares | 51.45M | 52.53M | 63.34M | 19.5M | 10.41M |
| Weighted Avg Shares (Diluted) | 51.45M | 52.53M | 63.34M | 19.5M | 10.41M |
Crescent Biopharma, Inc.
NASDAQ:CBIO
Intrinsic Alpha fair value
Locked
Current Price
$12.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.